Genome editing and gene therapy in Japan

Changes to the outlook for researcher-initiated gene therapies in Japan should help bring significant advances to important work, say experts.

Pentatricopeptide repeat (PPR) technology can precisely edit Both RNA and DNA. Free of CRISPR’s intellectual property mire, this system could revolutionize gene therapy.

Target-AID, a new mutagenesis-based gene-editing tool, opens the door to modified microbes, and a revolution in microbiome therapies.

Mitsubishi Tanabe Pharma Corporation has invested in cutting-edge gene therapy projects for critical limb ischaemia and haemophilia B, as well as a bold new research facility.

A long history of research on safe and efficient delivery has put Jichi Medical University at the centre of a number of important gene-therapy clinical trials for neurological disorders.